|
ไทย |
On Monday, June 30, 2025, Assoc. Prof. Surakit Nathisuwan, Dean of the Faculty of Pharmacy, Mahidol University (MUPY), participated in the signing ceremony of the Collaboration and License Agreement between (1) the Government Pharmaceutical Organization (GPO), (2) the Drugs for Neglected Diseases initiative (DNDi), and (3) Pharco Corporation. The event was held at the DNDi Head Office in Geneva, Switzerland. Distinguished signatories included Dr. Mingkwan Supanpong (Director of the Government Pharmaceutical Organization), Dr. Sherine Hassan Abbas Helmy (Chairman of the Board, Pharco Corporation), Ms. Vanessa Daniels (Director of the South-East Asia Office, DNDi), Dr. Yasser Mohamed Hassan Fayed (Corporate Business Development Director, Pharco Corporation), and Mr. Luis Pizarro (Executive Director, DNDi).
This collaboration aims to facilitate the introduction of Ravidasvir, a treatment for hepatitis C developed by DNDi and Pharco Corporation, for distribution in Thailand. Under this agreement, the Government Pharmaceutical Organization will be responsible for importing and registering the drug, while the Faculty of Pharmacy, Mahidol University, will provide technical support. The initiative seeks to enable Thai physicians and patients to access a safe, effective, and affordable hepatitis C treatment, which is a crucial strategy toward eliminating hepatitis C as a public health threat by 2030.
This partnership aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 3: Good Health and Well-being, by expanding access to essential, high-quality, and affordable medicines, reducing the burden of infectious diseases, and supporting equitable and comprehensive healthcare systems. Such efforts are expected to improve the quality of life for the population and strengthen national health security.
